Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein

Cytokine ◽  
1992 ◽  
Vol 4 (5) ◽  
pp. 361-368 ◽  
Author(s):  
Stanley P. Ballou ◽  
Gerard Lozanski
Keyword(s):  
Inflammatory Cytokine ◽  
Human Monocytes ◽  
Cytokine Release ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome

Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1067
Author(s):  
Oleksandr Oliynyk ◽  
Wojciech Barg ◽  
Anna Slifirczyk ◽  
Yanina Oliynyk ◽  
Vitaliy Gurianov ◽  
...  
Keyword(s):  
Macrophage Activation Syndrome ◽  
Macrophage Activation ◽  
Cytokine Storm ◽  
Cytokine Release ◽  
Cytokine Release Syndrome ◽  
C Reactive Protein ◽  
Treatment Results ◽  
Reactive Protein ◽  
Median Serum ◽  
D Dimer

Background: Cytokine storm in COVID-19 is heterogenous. There are at least three subtypes: cytokine release syndrome (CRS), macrophage activation syndrome (MAS), and sepsis. Methods: A retrospective study comprising 276 patients with SARS-CoV-2 pneumonia. All patients were tested for ferritin, interleukin-6, D-Dimer, fibrinogen, calcitonin, and C-reactive protein. According to the diagnostic criteria, three groups of patients with different subtypes of cytokine storm syndrome were identified: MAS, CRS or sepsis. In the MAS and CRS groups, treatment results were assessed depending on whether or not tocilizumab was used. Results: MAS was diagnosed in 9.1% of the patients examined, CRS in 81.8%, and sepsis in 9.1%. Median serum ferritin in patients with MAS was significantly higher (5894 vs. 984 vs. 957 ng/mL, p < 0.001) than in those with CRS or sepsis. Hypofibrinogenemia and pancytopenia were also observed in MAS patients. In CRS patients, a higher mortality rate was observed among those who received tocilizumab, 21 vs. 10 patients (p = 0.043), RR = 2.1 (95% CI 1.0–4.3). In MAS patients, tocilizumab decreased the mortality, 13 vs. 6 patients (p = 0.013), RR = 0.50 (95% CI 0.25–0.99). Сonclusions: Tocilizumab therapy in patients with COVID-19 and CRS was associated with increased mortality, while in MAS patients, it contributed to reduced mortality.

scholarly journals Correlation Between Early Plasma Interleukin 37 Responses With Low Inflammatory Cytokine Levels and Benign Clinical Outcomes in Severe Acute Respiratory Syndrome Coronavirus 2 Infection

2020 ◽  
Author(s):  
Ang Li ◽  
Yun Ling ◽  
Zhigang Song ◽  
Xiaobo Cheng ◽  
Longfei Ding ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Inflammatory Cytokine ◽  
Inflammatory Responses ◽  
Clinical Intervention ◽  
Protective Role ◽  
Interferon Α ◽  
Type I ◽  
C Reactive Protein ◽  
Clinical Prognosis ◽  
Reactive Protein

Abstract Background The immune protective mechanisms during severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection remain to be deciphered for the development of an effective intervention approach. Methods We examined early responses of interleukin 37 (IL-37), a powerful anti-inflammatory cytokine, in 254 SARS-CoV-2–infected patients before any clinical intervention and determined its correlation with clinical prognosis. Results Our results demonstrated that SARS-CoV-2 infection causes elevation of plasma IL-37. Higher early IL-37 responses were correlated with earlier viral RNA negative conversion, chest computed tomographic improvement, and cough relief, consequently resulted in earlier hospital discharge. Further assays showed that higher IL-37 was associated with lower interleukin 6 and interleukin 8 (IL-8) and higher interferon α responses and facilitated biochemical homeostasis. Low IL-37 responses predicted severe clinical prognosis in combination with IL-8 and C-reactive protein. In addition, we observed that IL-37 administration was able to attenuate lung inflammation and alleviate respiratory tissue damage in human angiotensin-converting enzyme 2–transgenic mice infected with SARS-CoV-2. Conclusions Overall, we found that IL-37 plays a protective role by antagonizing inflammatory responses while retaining type I interferon, thereby maintaining the functionalities of vital organs. IL-37, IL-8, and C-reactive protein might be formulated as a precise prediction model for screening severe clinical cases and have good value in clinical practice.

Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin

Cytokine ◽  
2007 ◽  
Vol 40 (3) ◽  
pp. 201-206 ◽  
Author(s):  
Wen-Lan Hu ◽  
Shu-Bing Qian ◽  
Jian-Jun Li
Keyword(s):  
Human Monocytes ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes

Rheumatology ◽  
2009 ◽  
Vol 48 (3) ◽  
pp. 233-242 ◽  
Author(s):  
F. Montecucco ◽  
F. Burger ◽  
G. Pelli ◽  
N. K. Poku ◽  
C. Berlier ◽  
...  
Keyword(s):  
Human Monocytes ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals Tocilizumab treatment and outcomes in severe COVID-19 patients: Retrospective study from a tertiary care institute in western India

2020 ◽  
Vol 8 (S1) ◽  
pp. 6-10
Author(s):  
Peta RK ◽  
Panchal HP ◽  
Patel A ◽  
Parikh S ◽  
Khanikar D ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Interleukin 6 ◽  
Respiratory Symptoms ◽  
Tertiary Care ◽  
Western India ◽  
Cytokine Storm ◽  
Cytokine Release ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Care Institute

Background: Coronavirus disease 2019 (COVID-19) is a pandemic caused by a novel beta coronavirus severe acute respiratory syndrome coronavirus (SARS-CoV-2). The symptoms range from mild to severe in nature. The severity of respiratory symptoms is due to the cytokine storm. The tocilizumab, interleukin-6 inhibitor, can prevent the cytokine release and decrease the mortality. Patients and methods: This is a retrospective observational study of 20 COVID-19 positive cases who received tocilizumab. Results and conclusion: There were 75% males with a mean age of 47.20±9.68 years in our study. 50% had diabetes mellitus, 35% had hypertension, 5% had Chronic kidney disease, 5% had obesity and 5% had hypothyroidism. Mortality was reduced to 65% with tocilizumab administration. There was statistically significant reduction of C- reactive protein (p<0.00052) and IL-6 (interleukin) (p<0.023) after administration of tocilizumab. Keywords: tocilizumab; interleukin-6; COVID-19; C-reactive protein

Sign in / Sign up

Export Citation Format

Share Document